Upcoming Issue Highlights


Numedica logo-400

9503 E. 55th Pl.
Tulsa, OK 74145
Phone: (800) 869-8100 • Fax: (877) 270-2005
Email: jose.rivas@numedica.com
Website: www.numedica.com/prenuphase

Glycemic Support and Weight Management Through the Control of Carbohydrate Absorption*

As you may see more and more in your practice, poor glucose control and insulin resistance are two of the most pervasive biomarkers associated with poor health conditions affecting more than 80 percent of Americans. Insulin resistance occurs for a variety of reasons, but in most cases, the key culprit is the diet that is laden with starchy foods with high sugar content. Researchers have suggested that an important factor of this growing issue is the increased intake of simple carbohydrates, particularly sugars that are rapidly absorbed.1

Your recommendation of a sensible diet and exercise plan is the cornerstone of your patients’ healthier metabolic management. However, if that plan included the supplementation of clinically researched nutritional ingredients that may help the patient begin to safely impact the absorption of glucose, support insulin receptors work more efficiently, and at the same time promote the amount of resistant starch that gets delivered to the large intestine; it could lead to dramatic improvements in health and well-being.*

L-Arabinose and Chromium Picolinate

The modulating effects of these two ingredients on glycemic response has been researched and supported by multiple clinical studies with significant results.1-4 In two human clinical studies, a patented, proprietary blend of these two ingredients was tested against a 70-gram glucose challenge. In both studies, as compared to the control groups, the supplement groups had significantly lower glycemic responses for all testing times, concluding that the consumption of the LA-Cr formula after a 70-gram glucose challenge was significantly effective in safely lowering both circulating glucose (-28.95 percent avg.) and insulin levels (-20.19 percent avg.).*1

White Kidney Bean Extract

Recently, there has been a shift towards the reduction carbohydrate intake, particularly simple carbohydrates, as an approach to manage excess weight.5 The digestion of carbohydrates begins with amylase secreted by the salivary glands. The alpha-amylase inhibitor properties of white kidney bean extract have been heavily studied with positive results in delaying the digestion and absorption of carbohydrates, thereby lowering their glycemic impact.5-7 Carbohydrates that are resistant to digestion in the small intestine are delivered to the large intestine where they act more like dietary fiber—feeding the microbiome and upregulating GLP-1 which regulates satiety signaling.

In a 12-week weight-loss and a subsequent 12-week weight-maintenance study, subjects were randomized to receive either a patented, proprietary extract of white kidney bean or a placebo. All subjects adhered to a mildly hypocaloric diet and body weight and other body composition parameters were measured at baseline and every four weeks thereafter. At the end of the 12-week weight-loss period, the treatment group lost a mean of 2.91 ± 2.63 kg in body weight compared with 0.92 ± 2.00 kg in the placebo group. During the weight-maintenance phase, 36 out of 49 subjects were able to maintain their weight, even without dietary restrictions.7

Panax Notoginseng and Astragalus membranaceus Blend

AMP-activated protein kinase (AMPK) has been shown to be a key regulator of glucose and lipid metabolism. Ginseng is well-known for its prominently hypoglycemic activity. In an effort to clarify the gluco-regulatory activity of ginsenosides, the main active component of ginseng, researchers studied its effects on human hepatoma HepG2 cells with positive results. Ginsenoside Rg1 was found to activate the PI3K and AMPK Pathways in HepG2 cells, thereby increasing fatty acid oxidation and inhibiting glucogenesis, hepatic lipogensis and glycogen biosynthesis.8-10

A Novel Approach to Glycemic Support and Metabolic Management*

PrenuPhase is an exclusive NuMedica formulation researched and developed by James LaValle, a nationally recognized clinical pharmacist and founder of the Metabolic Code (www.metaboliccode.com). This advanced formula features three patented ingredients offering comprehensive glycemic and metabolic management support.*

NuMedica is the leading manufacturer of research-driven clinical nutrition. Its mission and passion drive the company to remain the benchmark of excellence in nutritional quality, purity and safety. NuMedica is an NSF GMP (good manufacturing practice) and FDA (U.S. Food and Drug Administration)-registered company.

*These statements have not been evaluated by the food and drug administration. These products are not intended to diagnose, treat, cure or prevent any disease.


1 Kaats, et al., Nutrition Journal 2011; 10:42.

2 “A Pilot Study of the Effects of L-A/Cr: A Novel Combination of L-Arabinose and a Patented Chromium Supplement on Serum Glucose Levels After Sucrose Challenges,” Kaats, Preuss, et al., 2009.

3 Seri, et al., Metabolism 1996; 45: 1368-1374.

4 Cefalu, et al., The Journal of Trace Elements in Experimental Medicine 1999; 12:71-83.

5 Barrett, Udani, MD, Nutrition Journal, March 2011

6 Udani, et al, Nutrition Journal 2009, 8:52.

7 Grube, et al, Obesity, online 2013.

8 W.L. Chang, et al., Adaptive Medicine. 2013, 5(4), 181-188.

9 T.C. Chang, et al J. Agric. Food Chem. 2007, 55, 1993-1995.

10 C.W. Wang, et al, Molecular Pharmacology. 2015, 88, 1072-1083.